Integral Health Asset Management LLC Buys 250,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Integral Health Asset Management LLC increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 125.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 450,000 shares of the company’s stock after purchasing an additional 250,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Keros Therapeutics were worth $7,124,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in Keros Therapeutics by 585.9% in the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company’s stock worth $3,379,000 after purchasing an additional 182,314 shares during the period. SG Americas Securities LLC bought a new position in Keros Therapeutics in the 4th quarter worth $388,000. Darwin Global Management Ltd. raised its holdings in Keros Therapeutics by 10.7% during the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock valued at $26,707,000 after acquiring an additional 163,403 shares during the period. Barclays PLC raised its holdings in Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after acquiring an additional 35,022 shares during the period. Finally, Norges Bank bought a new stake in Keros Therapeutics during the fourth quarter valued at about $1,027,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Stock Performance

Shares of KROS opened at $13.65 on Monday. The company’s fifty day moving average is $12.20 and its 200 day moving average is $24.23. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a market capitalization of $554.39 million, a PE ratio of -2.62 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million for the quarter, compared to analysts’ expectations of $84.62 million. During the same quarter in the previous year, the business posted ($1.21) earnings per share. As a group, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business’s stock in a transaction on Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. The trade was a 27.01% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 20.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

KROS has been the topic of a number of recent analyst reports. Cantor Fitzgerald cut Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Piper Sandler decreased their price target on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. Truist Financial decreased their price target on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Scotiabank decreased their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday, January 16th. Finally, Wells Fargo & Company decreased their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.67.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.